147 related articles for article (PubMed ID: 883333)
1. Adjuvant combination chemotherapy with CMF in primary mammary carcinoma.
Veronesi U; Rossi A; Bonadonna G
World J Surg; 1977 May; 1(3):337-40. PubMed ID: 883333
[No Abstract] [Full Text] [Related]
2. Adjuvant combination chemotherapy in primary mammary carcinoma: the CMF program.
Rossi A; Bonadonna G; Valagussa P; Veronesi U
Recent Results Cancer Res; 1977; (62):134-42. PubMed ID: 341246
[No Abstract] [Full Text] [Related]
3. The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
Levitt SH; Potish RA
Cancer Clin Trials; 1981; 4(4):363-9. PubMed ID: 7032731
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy in the primary management of breast cancer.
Fisher B
Med Clin North Am; 1977 Sep; 61(5):953-65. PubMed ID: 330977
[No Abstract] [Full Text] [Related]
5. Present status of CMF adjuvant therapy in operable breast cancer.
Bonadonna G
Int J Radiat Oncol Biol Phys; 1977; 2(3-4):237-40. PubMed ID: 324955
[No Abstract] [Full Text] [Related]
6. [Evaluation of the toxicity of precautional chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in carcinoma of the breast in the first 700 treatment cycles].
Sismondi P; Zola P; Galletto L; De Giovanni D; Giardina G
Minerva Ginecol; 1979; 31(7-8):563-8. PubMed ID: 481814
[No Abstract] [Full Text] [Related]
7. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
[TBL] [Abstract][Full Text] [Related]
8. Surgery and adjuvant chemotherapy in the treatment of operable breast cancer.
Rossi A; Valagussa P; Bonadonna G
Prog Clin Biol Res; 1977; 12():391-404. PubMed ID: 335401
[No Abstract] [Full Text] [Related]
9. Grand Rounds: Adjuvant therapy of breast cancer.
Va Med; 1977 Oct; 104(10):709-15. PubMed ID: 919723
[No Abstract] [Full Text] [Related]
10. [Combination chemotherapy in advanced carcinoma of the breast].
Carmo-Pereira J; Galvão-Teles A; Oliveira Costa F; Bak Gordon R; Henriques E; Dória JM; Freire Cruz M; Silveira Botelho L
Arq Patol; 1974; 46(2-3):309-23. PubMed ID: 4458643
[No Abstract] [Full Text] [Related]
11. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
12. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
Bonadonna G; Rossi A; Valagussa P; Banfi A; Veronesi U
Cancer; 1977 Jun; 39(6 Suppl):2904-15. PubMed ID: 326384
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
14. [Adjuvant chemotherapy in breast cancer].
Senn HJ
Dtsch Med Wochenschr; 1981 Nov; 106(48):1626-30. PubMed ID: 7030686
[No Abstract] [Full Text] [Related]
15. Multimodal treatment in operable breast cancer: five-year results of the CMF programme.
Rossi A; Bonadonna G; Valagussa P; Veronesi U
Br Med J (Clin Res Ed); 1981 May; 282(6274):1427-31. PubMed ID: 6784849
[TBL] [Abstract][Full Text] [Related]
16. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
[TBL] [Abstract][Full Text] [Related]
17. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant chemotherapy of primary breast cancer].
Heuson JC; Mattheiem WH
Acta Chir Belg; 1977; 76(4):437-43. PubMed ID: 919991
[No Abstract] [Full Text] [Related]
19. [CMF (cyclophosphamide, methotrexate, ftorafur) chemotherapy in advanced breast cancer].
Gottwald G; Szakolczai I
Orv Hetil; 1983 Jan; 124(2):79-84. PubMed ID: 6687491
[No Abstract] [Full Text] [Related]
20. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
